Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study (NCT07509112) | Clinical Trial Compass
Not Yet RecruitingPhase 2
Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study
Australia40 participantsStarted 2026-05
Plain-language summary
Methamphetamine use disorder is a major public health concern in Australia and globally. GLP-1 medications such as semaglutide (e.g. Ozempic) are approved for diabetes and medication, and may potentially affect craving for other substances apart from food. We do not know if this will help people who use methamphetamine ('ice') to reduce their use. This study will treat people who use methamphetamine with weekly injections of semaglutide. It will provide data on if this is a potentially safe and practical treatment for this group of people.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Has provided voluntary, written informed consent;
✓. Aged 18 years or older;
✓. Diagnosed with moderate to severe methamphetamine use disorder (DSM-5 criteria);
✓. Self-reported methamphetamine use on at least 14 of past 28 days and a positive oral fluid drug screen for amphetamine/methamphetamine;
✓. Willing and able to comply with study procedures and follow-up visits;
✓. People of child-bearing potential must agree to use effective contraception during treatment and during the 60 days after treatment end.
Exclusion criteria
✕. Uncontrolled medical or psychiatric conditions that may interfere with participation;
✕. Body mass index less than 22 kg/m2;
✕. Confirmed diagnosis of diabetes mellitus (either known history of diabetes; concomitant treatment with insulin, metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitor, DPP4 inhibitor; or HbA1c \>6.5 at screening);
✕. Currently taking a GLP-1 receptor agonist;
✕. Known hypersensitivity or contraindications to GLP-1 receptor agonists as per product information;
✕. Current enrolment in another interventional trial;